Tag:
APD125
Latest Headlines
Latest Headlines
Arena shelves insomnia drug on trial failure
Shares of Arena Pharmaceuticals were dented after the developer announced that a Phase IIb trial of a new insomnia drug--APD125-- failed to hit its primary or secondary endpoints and will be shelved.
Arena Pharma produces positive insomnia data
San Diego-based Arena Pharmaceuticals has delivered positive mid-stage data on APD125, an experimental therapy for chronic insomnia. The therapy is being developed for people who have a hard time
